Tonix Pharmaceuticals' TNX-102 SL was designated fast-track status by the FDA. The candidate is being developed as a treatment of agitation in patients with Alzheimer's disease.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.